Company Encyclopedia
View More
name
WeigaoOrthopaedic
688161.SH
Shandong Weigao Orthopaedic Device Co., Ltd. operates as a orthopedic implant medical device and pharmaceutical company. The company offers general consumables, such as clinical care consumables and supplies, infection protection supplies, infusion consumables, indwelling needle, anesthesia respiratory consumables, other operating room consumables, and other clinical consumables; endocrine consumables; medical informationization solutions; and orthopedics products, including spine, joint, trauma, sports medicine, orthopedics devices, bone repair materials, and spinal endoscopy products. It also provides oral treatment equipment and dental implant consumables; platelet-rich plasma therapy and negative pressure drainage consumables; and blood purification products comprising hemodialysis equipment and consumables, peritoneal dialysis preparations, and hemodialysis equipment pipeline cleaning products.
886.85 B
688161.SHMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking10/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.68%C
    • Profit Margin18.08%A
    • Gross Margin67.88%A
  • Growth ScoreB
    • Revenue YoY14.90%B
    • Net Profit YoY72.62%A
    • Total Assets YoY1.51%C
    • Net Assets YoY4.17%C
  • Cash ScoreB
    • Cash Flow Margin552.98%C
    • OCF YoY14.90%B
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreA
    • Gearing Ratio19.76%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WEIGAO GROUP: WeigaoOrthopaedic's net profit attributable to the parent company in the first half of the year was 142 million yuan, a year-on-year increase of 52.43%

    According to the Zhitong Finance APP, WEIGAO GROUP released its performance for WeigaoOrthopaedic in the first half of 2025, with operating revenue of 741 million yuan (RMB, the same below), a year-on-year decrease of 1.28%; net profit attributable to shareholders of the listed company was 142 million yuan, a year-on-year increase of 52.43%; basic earnings per share were 0.35 yuan

    Zhitong·
    HK
    01066
    +0.95%
    SH
    688161
    +0.82%
    Zhitong·
    HK
    01066
    +0.95%
    SH
    688161
    +0.82%

    Bank of China International: The Medical Insurance Bureau clarifies that centralized procurement is against involution, focusing on re-evaluation opportunities in the pharmaceutical sector

    Bank of China International released a research report stating that the Medical Insurance Bureau has launched the 11th batch of centralized procurement, emphasizing the principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and resisting involution," while optimizing procurement rules. This centralized procurement will no longer simply reference the lowest price; companies with the lowest bids are required to publicly explain the rationale and commit to not quoting below cost. It is expected that as price expectations stabilize, the profitability of the pharmaceutical industry will gradually improve, and it is recommended to pay attention to the revaluation opportunities in the pharmaceutical sector

    Zhitong·
    SH
    603233
    +1.10%
    SH
    688621
    +6.99%
    SH
    600993
    +1.28%
    Zhitong·
    SH
    603233
    +1.10%
    SH
    688621
    +6.99%
    SH
    600993
    +1.28%

    Weigao Orthopaedic plans to launch a restricted stock incentive plan in 2025

    Weigao Orthopaedic released a draft of the 2025 restricted stock incentive plan, proposing to grant 7.2 million restricted shares, accounting for 1.80% of the company's total share capital. The initial grant will be 6.7 million shares, with 500,000 shares reserved, and the grant price is set at 13.89 yuan per share. The plan has a maximum validity period of 60 months

    Zhitong·
    SH
    688161
    +0.82%
    Zhitong·
    SH
    688161
    +0.82%

    Weigao Orthopaedic released its 2024 annual performance, with a net profit attributable to the parent company of 224 million yuan, a year-on-year increase of 99.22%

    Weigao Orthopaedic released its 2024 annual report, with operating revenue of 1.453 billion yuan, a year-on-year increase of 13.18%; net profit attributable to the parent company was 224 million yuan, a year-on-year increase of 99.22%. The net profit excluding non-recurring gains and losses was 211 million yuan, a year-on-year increase of 95.44%. The basic earnings per share were 0.56 yuan, and it is proposed to distribute a cash dividend of 1.70 yuan for every 10 shares. The company has increased its market share and achieved performance growth by adjusting its business strategy and optimizing management

    Zhitong·
    SH
    688161
    +0.82%
    Zhitong·
    SH
    688161
    +0.82%

    Weigao Orthopaedic: Net profit for the year 2024 is 222 million yuan, a year-on-year increase of 97.49%

    According to the Zhitong Finance APP, Weigao Orthopaedic released its 2024 annual performance report. During the reporting period, the company achieved operating revenue of 1.452 billion yuan, a year-on-year increase of 13.14%; the net profit attributable to the parent company's owners was 222 million yuan, a year-on-year increase of 97.49%; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 212 million yuan, a year-on-year increase of 96.29%; basic earnings per share were 0.55 yuan/share

    Zhitong·
    SH
    688161
    +0.82%
    Zhitong·
    SH
    688161
    +0.82%
    © 2025 Longbridge｜Disclaimer